Researchers believe they have found exactly how Kalydeco (Vx-770), the first drug of its kind to treat the underlying cause of cystic fibrosis, works and how to improve its effectiveness in the future.
Researchers believe they have found exactly how Kalydeco (Vx-770), the first drug of its kind to treat the underlying cause of cystic fibrosis, works and how to improve its effectiveness in the future.